Cymabay gets FDA nod on plans for phase III gout drug trials

Cymabay Therapeutics Inc. said the FDA has agreed to designs for a trio of pivotal phase III studies to test the company's oral, once-daily gout candidate, arhalofenate, with Uloric, a milestone that gives the company clarity that could help it launch the trials this year and secure a needed partner for the program as well.